Royalty Pharma plc Files 8-K for Regulation FD Disclosure
Ticker: RPRX · Form: 8-K · Filed: Dec 22, 2025 · CIK: 1802768
| Field | Detail |
|---|---|
| Company | Royalty Pharma PLC (RPRX) |
| Form Type | 8-K |
| Filed Date | Dec 22, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $5 b, $5 billion, $225 million, $225 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulation-fd
TL;DR
Royalty Pharma dropped an 8-K on 12/19, likely material info for investors.
AI Summary
Royalty Pharma plc announced a Regulation FD Disclosure on December 19, 2025. The filing, submitted on December 22, 2025, pertains to information that may be material to investors. The company's principal executive offices are located at 110 East 59th Street, New York, NY 10022.
Why It Matters
This filing ensures that material information is disclosed to all investors simultaneously, maintaining fair and transparent market practices.
Risk Assessment
Risk Level: low — The filing is a standard disclosure under Regulation FD and does not appear to contain negative financial news or significant operational changes.
Key Players & Entities
- Royalty Pharma plc (company) — Registrant
- December 19, 2025 (date) — Earliest event reported
- December 22, 2025 (date) — Filing date
- 110 East 59th Street, New York, New York 10022 (location) — Principal executive offices
FAQ
What is the primary purpose of this Form 8-K filing?
The primary purpose is to serve as a Current Report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, specifically for a Regulation FD Disclosure.
When was the earliest event reported in this filing?
The earliest event reported was on December 19, 2025.
On what date was this Form 8-K filed with the SEC?
This Form 8-K was filed on December 22, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at 110 East 59th Street, New York, New York 10022.
What is Royalty Pharma plc's standard industrial classification?
Royalty Pharma plc's standard industrial classification is Pharmaceutical Preparations [2834].
Filing Stats: 1,064 words · 4 min read · ~4 pages · Grade level 13.4 · Accepted 2025-12-22 11:37:20
Key Financial Figures
- $0.0001 — red Class A Ordinary Shares, par value $0.0001 per share RPRX The Nasdaq Stock Mar
- $5 b — royalty of 4.5% on MYQORZO sales up to $5 billion, decreasing to 1% on sales above
- $5 billion — illion, decreasing to 1% on sales above $5 billion. Additionally, in 2022, Royalty Pharm
- $225 million — Cytokinetics long-term capital of up to $225 million related to MYQORZO, all of which has be
- $225 m — tics additional launch capital of up to $225 million, of which $50 million has been dr
- $50 million — capital of up to $225 million, of which $50 million has been drawn. Based on the amount dra
- $523 million — wn to date, Royalty Pharma will receive $523 million in quarterly repayments over 10 years (
- $20 million — (1.9x the total amount drawn), of which $20 million has been repaid through September 30, 2
- $175 million — is also eligible to draw an additional $175 million within the next 12 months. Royalty Phar
Filing Documents
- d35067d8k.htm (8-K) — 27KB
- 0001193125-25-328100.txt ( ) — 137KB
- rprx-20251219.xsd (EX-101.SCH) — 3KB
- rprx-20251219_lab.xml (EX-101.LAB) — 17KB
- rprx-20251219_pre.xml (EX-101.PRE) — 11KB
- d35067d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This document contains statements that constitute "forward-looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma's strategies, financing plans, growth opportunities, market growth and plans for capital deployment. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," "expect," "may," "will," "would," "could" or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these
SIGNATURES
SIGNATURES Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ROYALTY PHARMA PLC Date: December 22, 2025 By: /s/ Terrance Coyne Terrance Coyne Chief Financial Officer